Finance-Funding

  1. Will The Finance And Funding Pendulum Swing Back To Black In 2023? 12/1/2022

    Our experts talk about everything from alternative financing arrangements to investment trends that biopharma execs should keep their eyes on.

  2. Aristea CEO Talks Rare Disease Endpoints And Parallel Fundraising 11/1/2022

    The CEO Of Aristea talks about the company’s unusual move to do both a series B round, but not as a crossover, while also making a deal with another pharma company.

  3. 5 Steps To Avoid Mismanaging Biopharma Grant Funds 11/1/2022

    Here’s how to ensure you’re successfully maximizing that infusion of money and setting yourself up for further success in the grant world.

  4. What Has Changed With The R&D Tax Credit? 10/3/2022

    : The R&D tax credit, an often overlooked and misunderstood opportunity for taxpayers, can be used to offset the cost of drug discovery.

  5. In A Tighter VC Environment, Biopharmas Need To Get Valuation Right 9/1/2022

    The rigor investors are demanding from emerging companies means that life sciences entrepreneurs need to double down on having clear and concise milestones and good strategic plans — a challenging proposition, especially for early-stage companies that typically do not have suitable market comparisons.

  6. Milestone Payments In Life Sciences M&A And Licensing Transactions 7/1/2022

    Now is an opportune time to take a fresh look at some key considerations regarding a common feature of M&As — payments that become due in the future upon the achievement of specified events, which are commonly known as “milestones.”

  7. Key Considerations In Early-Stage Biopharma Financing 5/2/2022

    After over two years of soaring IPO valuations and high stock prices, biotech had a reckoning in the back half of 2021.

  8. Is Biopharma Poised For Bigger Deals In 2022? 5/2/2022

    Biopharma companies are sitting on roughly $1.2 trillion in firepower, according to a recent report by Ernst & Young. But firepower to spend on deals — which includes cash, existing debt, and market capitalization — won’t necessarily translate into multibillion-dollar transactions, at least in the short term.

  9. Embracing Challenges And Executing A Successful IPO 5/2/2022

    John Jacobs, CEO of Harmony Biosciences, discusses the challenges and lessons learned from when his company transitioned from private to public.

  10. A Q&A With A Venture Capitalist/Genetic Medicines Executive 4/1/2022

    Small biotech companies can improve their fundraising prowess, despite choppy market conditions, by avoiding a few common mistakes. Telling a good story is the first step.